Special Issue "Autophagy in Cancer"

A special issue of Biology (ISSN 2079-7737).

Deadline for manuscript submissions: 30 November 2019.

Special Issue Editors

Dr. Nikolai Engedal
E-Mail Website
Guest Editor
Nordic EMBL Partnership for Molecular Medicine, Centre for Molecular Medicine Norway (NCMM), University of Oslo, Oslo, Norway
Interests: autophagy; cancer therapy; unfolded protein response; intracellular signaling; calcium; cell death
Prof. Mario Tschan
E-Mail Website
Guest Editor
Institute of Pathology, University of Bern, Bern, Switzerland
Interests: autophagy; CMA; acute myeloid leukemias; targeted cancer therapies; retinoids; transcription factors
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

The last two decades have witnessed a tremendous and ever-growing interest among basic, translational and clinical researchers in studying the role of autophagy in cancer and in exploiting the new knowledge to improve cancer prevention, diagnostics, prognostics and treatment. However, there have been very few focussed journal issues or books on this important topic.

In the Special Issue entitled “Autophagy in Cancer” we welcome the submission of original and review articles covering a broad range of aspects related to the biological and clinical relationship between autophagy- and cancer-associated processes. This may include topics related to cancer initiation, progression, migration, invasion, metastasis, diagnostics, prognostics, prevention, cancer therapy and treatment responses, the tumor-microenvironment and its interaction with cancer cells, inflammation, and cancer immunology. Moreover, we encourage articles focused on the intersections between autophagy and/or autophagy-related proteins with other cellular processes, including membrane trafficking and secretion events, metabolism, cell death mechanisms, intracellular signaling, gene expression, genome stability, and cellular stress responses.

We are looking forward to receiving your contributions to this Special Issue of Biology.

Dr. Nikolai Engedal
Prof. Mario Tschan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • autophagy
  • ATG
  • cancer
  • tumor biology
  • cancer therapy
  • therapy resistance
  • membrane trafficking
  • metabolism
  • cell death
  • cellular stress responses

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle
Cytotoxic Potential of the Coelomic Fluid Extracted from the Sea Cucumber Holothuria tubulosa against Triple-Negative MDA-MB231 Breast Cancer Cells
Biology 2019, 8(4), 76; https://doi.org/10.3390/biology8040076 - 09 Oct 2019
Abstract
Growing evidence has demonstrated that the extracts of different holothurian species exert beneficial effects on human health. Triple negative breast cancers (TNBC) are highly malignant tumors that present a poor prognosis due to the lack of effective targeted therapies. In the attempt to [...] Read more.
Growing evidence has demonstrated that the extracts of different holothurian species exert beneficial effects on human health. Triple negative breast cancers (TNBC) are highly malignant tumors that present a poor prognosis due to the lack of effective targeted therapies. In the attempt to identify novel compounds that might counteract TNBC cell growth, we studied the effect of the exposure of the TNBC cell line MDA-MB231 to total and filtered aqueous extracts of the coelomic fluid obtained from the sea cucumber Holoturia tubulosa, a widespread species in the Mediterranean Sea. In particular, we examined cell viability and proliferative behaviour, cell cycle distribution, apoptosis, autophagy, and mitochondrial metabolic/cell redox state. The results obtained indicate that both total and fractionated extracts are potent inhibitors of TNBC cell viability and growth, acting through both an impairment of cell cycle progression and mitochondrial transmembrane potential and a stimulation of cellular autophagy, as demonstrated by the increase of the acidic vesicular organelles and of the intracellular protein markers beclin-1, and total LC3 and LC3-II upon early exposure to the preparations. Identification of the water-soluble bioactive component(s) present in the extract merit further investigation aiming to develop novel prevention and/or treatment agents efficacious against highly metastatic breast carcinomas. Full article
(This article belongs to the Special Issue Autophagy in Cancer)
Show Figures

Graphical abstract

Review

Jump to: Research

Open AccessReview
Autophagy and Its Relationship to Epithelial to Mesenchymal Transition: When Autophagy Inhibition for Cancer Therapy Turns Counterproductive
Biology 2019, 8(4), 71; https://doi.org/10.3390/biology8040071 - 24 Sep 2019
Abstract
The manipulation of autophagy for cancer therapy has gained recent interest in clinical settings. Although inhibition of autophagy is currently being used in clinical trials for the treatment of several malignancies, autophagy has been shown to have diverse implications for normal cell homeostasis, [...] Read more.
The manipulation of autophagy for cancer therapy has gained recent interest in clinical settings. Although inhibition of autophagy is currently being used in clinical trials for the treatment of several malignancies, autophagy has been shown to have diverse implications for normal cell homeostasis, cancer cell survival, and signaling to cells in the tumor microenvironment. Among these implications and of relevance for cancer therapy, the autophagic process is known to be involved in the regulation of protein secretion, in tumor cell immunogenicity, and in the regulation of epithelial-to-mesenchymal transition (EMT), a critical step in the process of cancer cell invasion. In this work, we have reviewed recent evidence linking autophagy to the regulation of EMT in cancer and normal epithelial cells, and have discussed important implications for the manipulation of autophagy during cancer therapy. Full article
(This article belongs to the Special Issue Autophagy in Cancer)
Show Figures

Graphical abstract

Back to TopTop